MEDI 9600

Drug Profile

MEDI 9600

Alternative Names: FcγRIIA antibody - MedImmune

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Class Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIA antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 14 Jun 2017 Preclinical trials in Autoimmune disorders in USA (unspecified route) before June 2017
  • 14 Jun 2017 Interim pharmacodynamics data from preclinical studies in Autoimmune disorders presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top